financetom
Business
financetom
/
Business
/
Blue Bird Insider Sold Shares Worth $822,244, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Blue Bird Insider Sold Shares Worth $822,244, According to a Recent SEC Filing
Dec 18, 2024 12:30 PM

03:06 PM EST, 12/18/2024 (MT Newswires) -- Razvan Radulescu, Chief Financial Officer, on December 17, 2024, sold 19,171 shares in Blue Bird ( BLBD ) for $822,244. Following the Form 4 filing with the SEC, Radulescu has control over a total of 89,347 shares of the company, with 89,347 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1589526/000158952624000140/xslF345X05/wk-form4_1734552169.xml

Price: 43.02, Change: -1.36, Percent Change: -3.05

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Moleculin Biotech Shares Rise After Announcing Preclinical Data for Annamycin Targeting Venetoclax-Resistant Leukemia
Moleculin Biotech Shares Rise After Announcing Preclinical Data for Annamycin Targeting Venetoclax-Resistant Leukemia
Dec 11, 2024
01:33 PM EST, 12/11/2024 (MT Newswires) -- Moleculin Biotech's ( MBRX ) shares were up nearly 9% in recent Wednesday trading after the company announced preclinical data showcasing its drug candidate Annamycin's efficacy against venetoclax-resistant acute myeloid leukemia, or AML, cell lines. Presented at the American Society of Hematology's Annual Meeting, the study showed that Annamycin effectively targets Cytarabine, or...
What's Going On With Moleculin Biotech Shares Wednesday?
What's Going On With Moleculin Biotech Shares Wednesday?
Dec 11, 2024
Moleculin Biotech, Inc. ( MBRX ) shares are trading higher on Wednesday after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model. What To Know: The preclinical data suggests that Annamycin effectively targets acute myeloid leukemia (AML) cell lines resistant to Cytarabine (Ara-C) and Venetoclax (VEN) in lab tests using cells from patients...
Sector Update: Consumer
Sector Update: Consumer
Dec 11, 2024
01:30 PM EST, 12/11/2024 (MT Newswires) -- Consumer stocks were mixed Wednesday afternoon with the Consumer Staples Select Sector SPDR Fund (XLP) fractionally lower and the Consumer Discretionary Select Sector SPDR Fund (XLY) rising 1.6%. In corporate news, Albertsons ( ACI ) terminated its planned $25 billion acquisition by Kroger ( KR ) after two courts ruled to block the...
Comcast Business to Acquire Connectivity Services Provider Nitel From Cinven
Comcast Business to Acquire Connectivity Services Provider Nitel From Cinven
Dec 11, 2024
01:33 PM EST, 12/11/2024 (MT Newswires) -- Comcast ( CMCSA ) subsidiary Comcast Business said Wednesday it has agreed to acquire Nitel, a Chicago-based connectivity services provider, from private equity firm Cinven. Financial details weren't disclosed. Nitel provides network-as-a-service and managed solutions to 6,600 US enterprise customers in financial services, healthcare, and education industries. Price: 39.70, Change: +0.17, Percent Change:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved